�鶹ӰԺ

Cascade Bio, a �鶹ӰԺ spinout enabling enzyme-based processes, has secured $6 million to accelerate the shift from petrochemicals to biomanufacturing. The funding includes $3.2 million in non-dilutive funding from the U.S. National Science Foundation (NSF). With this investment, Cascade will expand delivery of its breakthrough biocatalysts.

Business Wire: Cascade Bio Secures $6M

The funding includes a $2.8M seed round led by Endurance28 with participation from Stray Dog Capital, 1Flourish, Range Ventures, 10VC, and Amplify plus $3.2M in nondilutive funding from the U.S. National Science Foundation (NSF) through the Advancing Cell-Free Systems Toward Increased Range of Use-Inspired Applications (NSF CFIRE) initiative and an SBIR Phase II award.

The University of Colorado Connection

Cascade Bio’s proprietary enzyme immobilization technology, dubbed “Body Armor,” acts as a cushion for the enzyme, enabling it to last longer, withstand more challenging conditions, and work across a wider operating window than other cell-free solutions. The technology was invented by co-founder ��while a graduate student in the CU �鶹ӰԺ laboratories of ��(CU �鶹ӰԺ Chemical and Biological Engineering) and ��(CU �鶹ӰԺ Chemical and Biological Engineering).��

View the Cascade Profile